vimarsana.com

Page 118 - உணர்ச்சி பல்கலைக்கழகம் பள்ளி ஆஃப் மருந்து News Today : Breaking News, Live Updates & Top Stories | Vimarsana

What should I know about COVID-19 vaccines if Im pregnant?

What should I know about COVID-19 vaccines if I’m pregnant? Vaccination is likely the best way to prevent COVID-19 in pregnancy, when risks for severe illness and death from the virus are higher than usual. The American College of Obstetricians and Gynecologists says COVID-19 vaccinations should not be withheld from pregnant women, and that women should discuss individual risks and benefits with their health care providers. The U.S. government’s emergency authorization for the Pfizer and Moderna vaccines being rolled out for priority groups doesn’t list pregnancy as a reason to withhold the shots. But the OB-GYN group says women should consult their doctors, since COVID-19 vaccines have not yet been tested in pregnant women. Evidence about safety and effectiveness is reassuring from studies that inadvertently included some women who didn’t know they were pregnant when they enrolled.

Should pregnant women get a COVID-19 vaccine?

U S vaccine shift stirs fresh unease as 128 million join line

U S vaccine shift stirs fresh unease as 128 million join line
lmtonline.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from lmtonline.com Daily Mail and Mail on Sunday newspapers.

GenSight Biologics Announces Publication of Results from LUMEVOQ RESCUE Pivotal Phase III Trial in AAO journal Ophthalmology

Regulatory News: GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on developing and commercializing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today announced that the journal of the American Academy of Ophthalmology, Ophthalmology ® gene therapy in ND4 Leber Hereditary Optic Neuropathy (LHON) subjects. The paper , published in the January issue under the title, “Efficacy and safety of intravitreal gene therapy for Leber hereditary optic neuropathy treated within 6 months of disease onset”, is the second peer-reviewed article based on Phase III clinical trial data to document comparable bilateral improvement in visual outcomes from a unilateral injection of a gene therapy.

Is one dose of the COVID-19 vaccine enough?

Is one dose of the COVID-19 vaccine enough? Kat Eschner © Provided by Popular Science In an ideal world, everyone would be receiving their second dose on schedule. But sloppy vaccine distribution and coordination efforts around the country could mean that many won’t get their second dose on time. In the last few weeks, approximately 5.3 million people received their first shot of one of two newly-authorized COVID-19 vaccines from drug makers Pfizer and Moderna. Like most vaccines, both of them require more than one shot to generate a high level of immune response. In late-stage clinical trials, both vaccines have been found to have a high efficacy after recipients have received both shots. The Moderna vaccine is 94.1 percent effective when the second dose is administered 28 days after the first. The Pfizer vaccine is 95 percent effective after the booster is given 21 days following the first shot.

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.